Jon Faiz Kayyem, Director at Inhibrx Biosciences, Inc. (INBX), bought 5,000 shares at $100.00 ($500K) on 2026-09-23, disclosed to the SEC on 2026-09-23.
Open-market purchase of $500k INBX by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| INBX | BUY | 2024-11-22 | $1.5M | — | Filing → |
| INBX | BUY | 2024-06-07 | $2.0M | — | Filing → |
| INBX | BUY | 2024-06-04 | $9.9M | — | Filing → |